PsyBio Therapeutics Corp. (PSYBF)

PsyBio Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	0.01	0	0.12	0.27
Short-Term Investments	-	-	3.68	-
Cash & Short-Term Investments	0.01	0	3.81	0.27
Cash Growth	-98.64%	-99.98%	1310.87%	-
Prepaid Expenses	0.09	0.09	0.19	0.02
Restricted Cash	-	0.16	-	-
Other Current Assets	-	0.01	-	-
Total Current Assets	0.11	0.25	4	0.29
Property, Plant & Equipment	0.17	0.13	-	-
Other Long-Term Assets	0.01	0.01	0.01	-
Total Assets	0.28	0.39	4.01	0.29
Accounts Payable	-	0.91	0.39	0.42
Accrued Expenses	1.39	0.43	0.05	0.1
Current Portion of Leases	0.1	0.14	-	-
Other Current Liabilities	0.49	0.51	0.6	0.5
Total Current Liabilities	1.97	1.98	1.04	1.02
Other Long-Term Liabilities	-	-	0.25	-
Total Liabilities	1.97	1.98	1.29	1.02
Common Stock	17.71	16.88	16.97	4.93
Retained Earnings	-22.87	-21.8	-16.92	-5.9
Comprehensive Income & Other	3.48	3.33	2.67	0.23
Shareholders' Equity	-1.69	-1.59	2.72	-0.74
Total Liabilities & Equity	0.28	0.39	4.01	0.29
Total Debt	0.1	0.14	-	-
Net Cash (Debt)	-0.08	-0.13	3.81	0.27
Net Cash Growth	-	-	1310.87%	-
Net Cash Per Share	-0.00	-0.00	0.04	0.01
Filing Date Shares Outstanding	132.61	132.61	112.57	58.24
Total Common Shares Outstanding	132.61	111.34	112.96	52.42
Working Capital	-1.86	-1.73	2.95	-0.74
Book Value Per Share	-0.01	-0.01	0.02	-0.01
Tangible Book Value	-1.69	-1.59	2.72	-0.74
Tangible Book Value Per Share	-0.01	-0.01	0.02	-0.01

Updated Aug 30, 2023. Source: S&P Global Market Intelligence. Standard template. Financial Sources.